nodes	percent_of_prediction	percent_of_DWPC	metapath
Tamoxifen—CYP1B1—Mitoxantrone—lymphatic system cancer	0.105	0.14	CbGbCtD
Tamoxifen—ABCB11—Vincristine—lymphatic system cancer	0.0723	0.0965	CbGbCtD
Tamoxifen—ABCG2—Teniposide—lymphatic system cancer	0.0714	0.0953	CbGbCtD
Tamoxifen—ABCG2—Mitoxantrone—lymphatic system cancer	0.0499	0.0667	CbGbCtD
Tamoxifen—CYP1A2—Carmustine—lymphatic system cancer	0.0438	0.0585	CbGbCtD
Tamoxifen—CYP3A5—Teniposide—lymphatic system cancer	0.0396	0.0528	CbGbCtD
Tamoxifen—ABCC2—Vincristine—lymphatic system cancer	0.038	0.0507	CbGbCtD
Tamoxifen—CYP2E1—Mitoxantrone—lymphatic system cancer	0.0356	0.0475	CbGbCtD
Tamoxifen—ABCG2—Vincristine—lymphatic system cancer	0.0344	0.0459	CbGbCtD
Tamoxifen—CYP2C19—Teniposide—lymphatic system cancer	0.0319	0.0426	CbGbCtD
Tamoxifen—CYP2C9—Teniposide—lymphatic system cancer	0.0265	0.0354	CbGbCtD
Tamoxifen—CYP3A7-CYP3A51P—Vincristine—lymphatic system cancer	0.0254	0.0339	CbGbCtD
Tamoxifen—CYP3A7—Vincristine—lymphatic system cancer	0.0254	0.0339	CbGbCtD
Tamoxifen—ABCC2—Methotrexate—lymphatic system cancer	0.023	0.0307	CbGbCtD
Tamoxifen—ABCG2—Methotrexate—lymphatic system cancer	0.0208	0.0278	CbGbCtD
Tamoxifen—CYP3A5—Vincristine—lymphatic system cancer	0.019	0.0254	CbGbCtD
Tamoxifen—ABCB1—Mitoxantrone—lymphatic system cancer	0.018	0.024	CbGbCtD
Tamoxifen—CYP3A4—Cytarabine—lymphatic system cancer	0.0157	0.0209	CbGbCtD
Tamoxifen—CYP3A4—Teniposide—lymphatic system cancer	0.0154	0.0206	CbGbCtD
Tamoxifen—ABCB1—Vincristine—lymphatic system cancer	0.0124	0.0165	CbGbCtD
Tamoxifen—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0108	0.0144	CbGbCtD
Tamoxifen—ABCB1—Methotrexate—lymphatic system cancer	0.0075	0.01	CbGbCtD
Tamoxifen—CYP3A4—Vincristine—lymphatic system cancer	0.00742	0.00991	CbGbCtD
Tamoxifen—EBP—Azacitidine—Fludarabine—lymphatic system cancer	0.00133	0.514	CbGdCrCtD
Tamoxifen—EBP—Azacitidine—Cytarabine—lymphatic system cancer	0.00125	0.486	CbGdCrCtD
Tamoxifen—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.000401	0.00161	CcSEcCtD
Tamoxifen—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.000399	0.00161	CcSEcCtD
Tamoxifen—Pneumonia—Vincristine—lymphatic system cancer	0.000399	0.00161	CcSEcCtD
Tamoxifen—Flushing—Bleomycin—lymphatic system cancer	0.000397	0.0016	CcSEcCtD
Tamoxifen—Depression—Vincristine—lymphatic system cancer	0.000396	0.00159	CcSEcCtD
Tamoxifen—Anorexia—Fludarabine—lymphatic system cancer	0.000395	0.00159	CcSEcCtD
Tamoxifen—Weight increased—Mitoxantrone—lymphatic system cancer	0.000395	0.00159	CcSEcCtD
Tamoxifen—Weight decreased—Mitoxantrone—lymphatic system cancer	0.000392	0.00158	CcSEcCtD
Tamoxifen—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.000391	0.00158	CcSEcCtD
Tamoxifen—Myocardial infarction—Vincristine—lymphatic system cancer	0.000389	0.00157	CcSEcCtD
Tamoxifen—Pneumonia—Mitoxantrone—lymphatic system cancer	0.000389	0.00157	CcSEcCtD
Tamoxifen—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000386	0.00155	CcSEcCtD
Tamoxifen—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.000381	0.00154	CcSEcCtD
Tamoxifen—Sweating—Vincristine—lymphatic system cancer	0.000381	0.00153	CcSEcCtD
Tamoxifen—Nausea—Mechlorethamine—lymphatic system cancer	0.00038	0.00153	CcSEcCtD
Tamoxifen—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.000379	0.00153	CcSEcCtD
Tamoxifen—Alopecia—Bleomycin—lymphatic system cancer	0.000378	0.00152	CcSEcCtD
Tamoxifen—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.000378	0.00152	CcSEcCtD
Tamoxifen—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.000376	0.00151	CcSEcCtD
Tamoxifen—Haemoglobin—Carmustine—lymphatic system cancer	0.000375	0.00151	CcSEcCtD
Tamoxifen—Urticaria—Teniposide—lymphatic system cancer	0.000375	0.00151	CcSEcCtD
Tamoxifen—Haemorrhage—Carmustine—lymphatic system cancer	0.000373	0.0015	CcSEcCtD
Tamoxifen—Abdominal pain—Teniposide—lymphatic system cancer	0.000373	0.0015	CcSEcCtD
Tamoxifen—Erythema—Bleomycin—lymphatic system cancer	0.000372	0.0015	CcSEcCtD
Tamoxifen—Paraesthesia—Fludarabine—lymphatic system cancer	0.000372	0.0015	CcSEcCtD
Tamoxifen—Hypoaesthesia—Carmustine—lymphatic system cancer	0.000371	0.0015	CcSEcCtD
Tamoxifen—Sweating—Mitoxantrone—lymphatic system cancer	0.000371	0.00149	CcSEcCtD
Tamoxifen—Dyspnoea—Fludarabine—lymphatic system cancer	0.000369	0.00149	CcSEcCtD
Tamoxifen—Oedema peripheral—Carmustine—lymphatic system cancer	0.000368	0.00148	CcSEcCtD
Tamoxifen—Dyspepsia—Fludarabine—lymphatic system cancer	0.000365	0.00147	CcSEcCtD
Tamoxifen—Sinusitis—Mitoxantrone—lymphatic system cancer	0.000363	0.00146	CcSEcCtD
Tamoxifen—Decreased appetite—Fludarabine—lymphatic system cancer	0.00036	0.00145	CcSEcCtD
Tamoxifen—Visual impairment—Carmustine—lymphatic system cancer	0.00036	0.00145	CcSEcCtD
Tamoxifen—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.000358	0.00144	CcSEcCtD
Tamoxifen—Fatigue—Fludarabine—lymphatic system cancer	0.000357	0.00144	CcSEcCtD
Tamoxifen—Inflammation—Methotrexate—lymphatic system cancer	0.000355	0.00143	CcSEcCtD
Tamoxifen—Hypoaesthesia—Vincristine—lymphatic system cancer	0.000355	0.00143	CcSEcCtD
Tamoxifen—Pain—Fludarabine—lymphatic system cancer	0.000354	0.00143	CcSEcCtD
Tamoxifen—Constipation—Fludarabine—lymphatic system cancer	0.000354	0.00143	CcSEcCtD
Tamoxifen—Vasculitis—Methotrexate—lymphatic system cancer	0.000353	0.00142	CcSEcCtD
Tamoxifen—Haemoglobin—Mitoxantrone—lymphatic system cancer	0.000349	0.00141	CcSEcCtD
Tamoxifen—Hypersensitivity—Teniposide—lymphatic system cancer	0.000347	0.0014	CcSEcCtD
Tamoxifen—Haemorrhage—Mitoxantrone—lymphatic system cancer	0.000347	0.0014	CcSEcCtD
Tamoxifen—Hepatitis—Mitoxantrone—lymphatic system cancer	0.000347	0.0014	CcSEcCtD
Tamoxifen—Flushing—Carmustine—lymphatic system cancer	0.000346	0.0014	CcSEcCtD
Tamoxifen—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.000344	0.00139	CcSEcCtD
Tamoxifen—Vaginal inflammation—Methotrexate—lymphatic system cancer	0.000344	0.00139	CcSEcCtD
Tamoxifen—Pulmonary embolism—Methotrexate—lymphatic system cancer	0.000344	0.00139	CcSEcCtD
Tamoxifen—Anaemia—Bleomycin—lymphatic system cancer	0.000344	0.00139	CcSEcCtD
Tamoxifen—Asthenia—Teniposide—lymphatic system cancer	0.000338	0.00136	CcSEcCtD
Tamoxifen—Pruritus—Teniposide—lymphatic system cancer	0.000334	0.00134	CcSEcCtD
Tamoxifen—Arrhythmia—Carmustine—lymphatic system cancer	0.000334	0.00134	CcSEcCtD
Tamoxifen—Leukopenia—Bleomycin—lymphatic system cancer	0.000333	0.00134	CcSEcCtD
Tamoxifen—Alopecia—Carmustine—lymphatic system cancer	0.00033	0.00133	CcSEcCtD
Tamoxifen—Skin exfoliation—Methotrexate—lymphatic system cancer	0.000329	0.00132	CcSEcCtD
Tamoxifen—Vaginal infection—Methotrexate—lymphatic system cancer	0.000325	0.00131	CcSEcCtD
Tamoxifen—Erythema—Carmustine—lymphatic system cancer	0.000325	0.00131	CcSEcCtD
Tamoxifen—Cough—Bleomycin—lymphatic system cancer	0.000325	0.00131	CcSEcCtD
Tamoxifen—Diarrhoea—Teniposide—lymphatic system cancer	0.000323	0.0013	CcSEcCtD
Tamoxifen—Chest pain—Bleomycin—lymphatic system cancer	0.000317	0.00128	CcSEcCtD
Tamoxifen—Myalgia—Bleomycin—lymphatic system cancer	0.000317	0.00128	CcSEcCtD
Tamoxifen—Alopecia—Vincristine—lymphatic system cancer	0.000315	0.00127	CcSEcCtD
Tamoxifen—Back pain—Carmustine—lymphatic system cancer	0.000314	0.00127	CcSEcCtD
Tamoxifen—Discomfort—Bleomycin—lymphatic system cancer	0.000313	0.00126	CcSEcCtD
Tamoxifen—Neoplasm—Methotrexate—lymphatic system cancer	0.000311	0.00125	CcSEcCtD
Tamoxifen—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00031	0.00125	CcSEcCtD
Tamoxifen—Alopecia—Mitoxantrone—lymphatic system cancer	0.000307	0.00124	CcSEcCtD
Tamoxifen—Hypersensitivity—Fludarabine—lymphatic system cancer	0.000305	0.00123	CcSEcCtD
Tamoxifen—Oedema—Bleomycin—lymphatic system cancer	0.000304	0.00122	CcSEcCtD
Tamoxifen—Erythema—Mitoxantrone—lymphatic system cancer	0.000302	0.00122	CcSEcCtD
Tamoxifen—Infection—Bleomycin—lymphatic system cancer	0.000302	0.00122	CcSEcCtD
Tamoxifen—Anaemia—Carmustine—lymphatic system cancer	0.0003	0.00121	CcSEcCtD
Tamoxifen—Back pain—Vincristine—lymphatic system cancer	0.0003	0.00121	CcSEcCtD
Tamoxifen—Vomiting—Teniposide—lymphatic system cancer	0.0003	0.00121	CcSEcCtD
Tamoxifen—Sepsis—Methotrexate—lymphatic system cancer	0.000299	0.0012	CcSEcCtD
Tamoxifen—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000298	0.0012	CcSEcCtD
Tamoxifen—Asthenia—Fludarabine—lymphatic system cancer	0.000297	0.0012	CcSEcCtD
Tamoxifen—Rash—Teniposide—lymphatic system cancer	0.000297	0.0012	CcSEcCtD
Tamoxifen—Dermatitis—Teniposide—lymphatic system cancer	0.000297	0.0012	CcSEcCtD
Tamoxifen—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.000296	0.00119	CcSEcCtD
Tamoxifen—Headache—Teniposide—lymphatic system cancer	0.000295	0.00119	CcSEcCtD
Tamoxifen—Pruritus—Fludarabine—lymphatic system cancer	0.000293	0.00118	CcSEcCtD
Tamoxifen—Back pain—Mitoxantrone—lymphatic system cancer	0.000292	0.00118	CcSEcCtD
Tamoxifen—Leukopenia—Carmustine—lymphatic system cancer	0.000291	0.00117	CcSEcCtD
Tamoxifen—Anorexia—Bleomycin—lymphatic system cancer	0.00029	0.00117	CcSEcCtD
Tamoxifen—Anaemia—Vincristine—lymphatic system cancer	0.000287	0.00116	CcSEcCtD
Tamoxifen—Diarrhoea—Fludarabine—lymphatic system cancer	0.000284	0.00114	CcSEcCtD
Tamoxifen—Hypertension—Carmustine—lymphatic system cancer	0.000281	0.00113	CcSEcCtD
Tamoxifen—Nausea—Teniposide—lymphatic system cancer	0.00028	0.00113	CcSEcCtD
Tamoxifen—Anaemia—Mitoxantrone—lymphatic system cancer	0.000279	0.00113	CcSEcCtD
Tamoxifen—Hepatic failure—Methotrexate—lymphatic system cancer	0.000278	0.00112	CcSEcCtD
Tamoxifen—Leukopenia—Vincristine—lymphatic system cancer	0.000278	0.00112	CcSEcCtD
Tamoxifen—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000277	0.00112	CcSEcCtD
Tamoxifen—Chest pain—Carmustine—lymphatic system cancer	0.000277	0.00111	CcSEcCtD
Tamoxifen—Myalgia—Carmustine—lymphatic system cancer	0.000277	0.00111	CcSEcCtD
Tamoxifen—Anxiety—Carmustine—lymphatic system cancer	0.000276	0.00111	CcSEcCtD
Tamoxifen—Paraesthesia—Bleomycin—lymphatic system cancer	0.000273	0.0011	CcSEcCtD
Tamoxifen—Dyspnoea—Bleomycin—lymphatic system cancer	0.000271	0.00109	CcSEcCtD
Tamoxifen—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00027	0.00109	CcSEcCtD
Tamoxifen—Hypertension—Vincristine—lymphatic system cancer	0.000268	0.00108	CcSEcCtD
Tamoxifen—Oedema—Carmustine—lymphatic system cancer	0.000265	0.00107	CcSEcCtD
Tamoxifen—Decreased appetite—Bleomycin—lymphatic system cancer	0.000264	0.00106	CcSEcCtD
Tamoxifen—Myalgia—Vincristine—lymphatic system cancer	0.000264	0.00106	CcSEcCtD
Tamoxifen—Visual disturbance—Methotrexate—lymphatic system cancer	0.000264	0.00106	CcSEcCtD
Tamoxifen—Cough—Mitoxantrone—lymphatic system cancer	0.000264	0.00106	CcSEcCtD
Tamoxifen—Infection—Carmustine—lymphatic system cancer	0.000264	0.00106	CcSEcCtD
Tamoxifen—Vomiting—Fludarabine—lymphatic system cancer	0.000264	0.00106	CcSEcCtD
Tamoxifen—Rash—Fludarabine—lymphatic system cancer	0.000261	0.00105	CcSEcCtD
Tamoxifen—Dermatitis—Fludarabine—lymphatic system cancer	0.000261	0.00105	CcSEcCtD
Tamoxifen—Hypertension—Mitoxantrone—lymphatic system cancer	0.000261	0.00105	CcSEcCtD
Tamoxifen—Pain—Bleomycin—lymphatic system cancer	0.00026	0.00105	CcSEcCtD
Tamoxifen—Thrombocytopenia—Carmustine—lymphatic system cancer	0.00026	0.00105	CcSEcCtD
Tamoxifen—Headache—Fludarabine—lymphatic system cancer	0.00026	0.00105	CcSEcCtD
Tamoxifen—Arthralgia—Mitoxantrone—lymphatic system cancer	0.000257	0.00104	CcSEcCtD
Tamoxifen—Myalgia—Mitoxantrone—lymphatic system cancer	0.000257	0.00104	CcSEcCtD
Tamoxifen—Chest pain—Mitoxantrone—lymphatic system cancer	0.000257	0.00104	CcSEcCtD
Tamoxifen—Anxiety—Mitoxantrone—lymphatic system cancer	0.000256	0.00103	CcSEcCtD
Tamoxifen—Discomfort—Mitoxantrone—lymphatic system cancer	0.000254	0.00102	CcSEcCtD
Tamoxifen—Oedema—Vincristine—lymphatic system cancer	0.000253	0.00102	CcSEcCtD
Tamoxifen—Anorexia—Carmustine—lymphatic system cancer	0.000253	0.00102	CcSEcCtD
Tamoxifen—Infection—Vincristine—lymphatic system cancer	0.000252	0.00101	CcSEcCtD
Tamoxifen—Osteoarthritis—Methotrexate—lymphatic system cancer	0.00025	0.00101	CcSEcCtD
Tamoxifen—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000248	0.000999	CcSEcCtD
Tamoxifen—Oedema—Mitoxantrone—lymphatic system cancer	0.000247	0.000993	CcSEcCtD
Tamoxifen—Nausea—Fludarabine—lymphatic system cancer	0.000246	0.000992	CcSEcCtD
Tamoxifen—Infection—Mitoxantrone—lymphatic system cancer	0.000245	0.000987	CcSEcCtD
Tamoxifen—Hyperhidrosis—Vincristine—lymphatic system cancer	0.000245	0.000986	CcSEcCtD
Tamoxifen—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000242	0.000974	CcSEcCtD
Tamoxifen—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000241	0.000973	CcSEcCtD
Tamoxifen—Urticaria—Bleomycin—lymphatic system cancer	0.000241	0.000973	CcSEcCtD
Tamoxifen—Anorexia—Vincristine—lymphatic system cancer	0.000241	0.000972	CcSEcCtD
Tamoxifen—Insomnia—Carmustine—lymphatic system cancer	0.00024	0.000967	CcSEcCtD
Tamoxifen—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.000238	0.00096	CcSEcCtD
Tamoxifen—Paraesthesia—Carmustine—lymphatic system cancer	0.000238	0.00096	CcSEcCtD
Tamoxifen—Mood swings—Methotrexate—lymphatic system cancer	0.000237	0.000954	CcSEcCtD
Tamoxifen—Dyspnoea—Carmustine—lymphatic system cancer	0.000236	0.000953	CcSEcCtD
Tamoxifen—Anorexia—Mitoxantrone—lymphatic system cancer	0.000235	0.000947	CcSEcCtD
Tamoxifen—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000231	0.00093	CcSEcCtD
Tamoxifen—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000231	0.000929	CcSEcCtD
Tamoxifen—Decreased appetite—Carmustine—lymphatic system cancer	0.000231	0.000929	CcSEcCtD
Tamoxifen—Insomnia—Vincristine—lymphatic system cancer	0.000229	0.000923	CcSEcCtD
Tamoxifen—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000229	0.000923	CcSEcCtD
Tamoxifen—Paraesthesia—Vincristine—lymphatic system cancer	0.000227	0.000916	CcSEcCtD
Tamoxifen—Pain—Carmustine—lymphatic system cancer	0.000227	0.000914	CcSEcCtD
Tamoxifen—Constipation—Carmustine—lymphatic system cancer	0.000227	0.000914	CcSEcCtD
Tamoxifen—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000225	0.000905	CcSEcCtD
Tamoxifen—Hypersensitivity—Bleomycin—lymphatic system cancer	0.000224	0.000902	CcSEcCtD
Tamoxifen—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000221	0.000892	CcSEcCtD
Tamoxifen—Decreased appetite—Vincristine—lymphatic system cancer	0.00022	0.000887	CcSEcCtD
Tamoxifen—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00022	0.000886	CcSEcCtD
Tamoxifen—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000219	0.000881	CcSEcCtD
Tamoxifen—Fatigue—Vincristine—lymphatic system cancer	0.000218	0.00088	CcSEcCtD
Tamoxifen—Asthenia—Bleomycin—lymphatic system cancer	0.000218	0.000878	CcSEcCtD
Tamoxifen—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.000217	0.000875	CcSEcCtD
Tamoxifen—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000217	0.000874	CcSEcCtD
Tamoxifen—Pain—Vincristine—lymphatic system cancer	0.000217	0.000872	CcSEcCtD
Tamoxifen—Constipation—Vincristine—lymphatic system cancer	0.000217	0.000872	CcSEcCtD
Tamoxifen—Pruritus—Bleomycin—lymphatic system cancer	0.000215	0.000866	CcSEcCtD
Tamoxifen—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000214	0.000864	CcSEcCtD
Tamoxifen—Fatigue—Mitoxantrone—lymphatic system cancer	0.000213	0.000857	CcSEcCtD
Tamoxifen—Pancreatitis—Methotrexate—lymphatic system cancer	0.000212	0.000853	CcSEcCtD
Tamoxifen—Constipation—Mitoxantrone—lymphatic system cancer	0.000211	0.00085	CcSEcCtD
Tamoxifen—Pain—Mitoxantrone—lymphatic system cancer	0.000211	0.00085	CcSEcCtD
Tamoxifen—Abdominal pain—Carmustine—lymphatic system cancer	0.00021	0.000845	CcSEcCtD
Tamoxifen—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.000207	0.000834	CcSEcCtD
Tamoxifen—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000207	0.000834	CcSEcCtD
Tamoxifen—Pancytopenia—Methotrexate—lymphatic system cancer	0.000205	0.000827	CcSEcCtD
Tamoxifen—Neutropenia—Methotrexate—lymphatic system cancer	0.000202	0.000814	CcSEcCtD
Tamoxifen—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000202	0.000812	CcSEcCtD
Tamoxifen—Abdominal pain—Vincristine—lymphatic system cancer	0.0002	0.000806	CcSEcCtD
Tamoxifen—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.000199	0.000802	CcSEcCtD
Tamoxifen—Urticaria—Mitoxantrone—lymphatic system cancer	0.000196	0.000789	CcSEcCtD
Tamoxifen—Hypersensitivity—Carmustine—lymphatic system cancer	0.000195	0.000787	CcSEcCtD
Tamoxifen—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.000195	0.000785	CcSEcCtD
Tamoxifen—Pneumonia—Methotrexate—lymphatic system cancer	0.000194	0.000781	CcSEcCtD
Tamoxifen—Vomiting—Bleomycin—lymphatic system cancer	0.000193	0.000778	CcSEcCtD
Tamoxifen—Depression—Methotrexate—lymphatic system cancer	0.000192	0.000774	CcSEcCtD
Tamoxifen—Rash—Bleomycin—lymphatic system cancer	0.000192	0.000772	CcSEcCtD
Tamoxifen—Dermatitis—Bleomycin—lymphatic system cancer	0.000191	0.000771	CcSEcCtD
Tamoxifen—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000191	0.000769	CcSEcCtD
Tamoxifen—Asthenia—Carmustine—lymphatic system cancer	0.00019	0.000767	CcSEcCtD
Tamoxifen—Hypersensitivity—Vincristine—lymphatic system cancer	0.000187	0.000752	CcSEcCtD
Tamoxifen—Sweating—Methotrexate—lymphatic system cancer	0.000185	0.000744	CcSEcCtD
Tamoxifen—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000182	0.000732	CcSEcCtD
Tamoxifen—Asthenia—Vincristine—lymphatic system cancer	0.000182	0.000732	CcSEcCtD
Tamoxifen—Diarrhoea—Carmustine—lymphatic system cancer	0.000181	0.000731	CcSEcCtD
Tamoxifen—Nausea—Bleomycin—lymphatic system cancer	0.00018	0.000727	CcSEcCtD
Tamoxifen—Asthenia—Mitoxantrone—lymphatic system cancer	0.000177	0.000713	CcSEcCtD
Tamoxifen—Dizziness—Carmustine—lymphatic system cancer	0.000175	0.000707	CcSEcCtD
Tamoxifen—Haemoglobin—Methotrexate—lymphatic system cancer	0.000174	0.0007	CcSEcCtD
Tamoxifen—Diarrhoea—Vincristine—lymphatic system cancer	0.000173	0.000698	CcSEcCtD
Tamoxifen—Haemorrhage—Methotrexate—lymphatic system cancer	0.000173	0.000697	CcSEcCtD
Tamoxifen—Hepatitis—Methotrexate—lymphatic system cancer	0.000173	0.000697	CcSEcCtD
Tamoxifen—Pharyngitis—Methotrexate—lymphatic system cancer	0.000172	0.000691	CcSEcCtD
Tamoxifen—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000169	0.00068	CcSEcCtD
Tamoxifen—Vomiting—Carmustine—lymphatic system cancer	0.000169	0.000679	CcSEcCtD
Tamoxifen—Dizziness—Vincristine—lymphatic system cancer	0.000167	0.000675	CcSEcCtD
Tamoxifen—Rash—Carmustine—lymphatic system cancer	0.000167	0.000674	CcSEcCtD
Tamoxifen—Dermatitis—Carmustine—lymphatic system cancer	0.000167	0.000673	CcSEcCtD
Tamoxifen—Visual impairment—Methotrexate—lymphatic system cancer	0.000167	0.000671	CcSEcCtD
Tamoxifen—Headache—Carmustine—lymphatic system cancer	0.000166	0.000669	CcSEcCtD
Tamoxifen—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000164	0.000659	CcSEcCtD
Tamoxifen—Vomiting—Vincristine—lymphatic system cancer	0.000161	0.000649	CcSEcCtD
Tamoxifen—Rash—Vincristine—lymphatic system cancer	0.00016	0.000643	CcSEcCtD
Tamoxifen—Dermatitis—Vincristine—lymphatic system cancer	0.000159	0.000643	CcSEcCtD
Tamoxifen—Headache—Vincristine—lymphatic system cancer	0.000159	0.000639	CcSEcCtD
Tamoxifen—Nausea—Carmustine—lymphatic system cancer	0.000158	0.000635	CcSEcCtD
Tamoxifen—Vomiting—Mitoxantrone—lymphatic system cancer	0.000157	0.000632	CcSEcCtD
Tamoxifen—Rash—Mitoxantrone—lymphatic system cancer	0.000155	0.000626	CcSEcCtD
Tamoxifen—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000155	0.000626	CcSEcCtD
Tamoxifen—Headache—Mitoxantrone—lymphatic system cancer	0.000154	0.000622	CcSEcCtD
Tamoxifen—Alopecia—Methotrexate—lymphatic system cancer	0.000153	0.000616	CcSEcCtD
Tamoxifen—Erythema—Methotrexate—lymphatic system cancer	0.000151	0.000607	CcSEcCtD
Tamoxifen—Nausea—Vincristine—lymphatic system cancer	0.00015	0.000606	CcSEcCtD
Tamoxifen—Dysgeusia—Methotrexate—lymphatic system cancer	0.000147	0.000594	CcSEcCtD
Tamoxifen—Nausea—Mitoxantrone—lymphatic system cancer	0.000146	0.00059	CcSEcCtD
Tamoxifen—Back pain—Methotrexate—lymphatic system cancer	0.000146	0.000587	CcSEcCtD
Tamoxifen—Anaemia—Methotrexate—lymphatic system cancer	0.000139	0.000561	CcSEcCtD
Tamoxifen—Leukopenia—Methotrexate—lymphatic system cancer	0.000135	0.000543	CcSEcCtD
Tamoxifen—Cough—Methotrexate—lymphatic system cancer	0.000131	0.000529	CcSEcCtD
Tamoxifen—Arthralgia—Methotrexate—lymphatic system cancer	0.000128	0.000516	CcSEcCtD
Tamoxifen—Chest pain—Methotrexate—lymphatic system cancer	0.000128	0.000516	CcSEcCtD
Tamoxifen—Myalgia—Methotrexate—lymphatic system cancer	0.000128	0.000516	CcSEcCtD
Tamoxifen—Discomfort—Methotrexate—lymphatic system cancer	0.000127	0.00051	CcSEcCtD
Tamoxifen—Infection—Methotrexate—lymphatic system cancer	0.000122	0.000492	CcSEcCtD
Tamoxifen—Thrombocytopenia—Methotrexate—lymphatic system cancer	0.00012	0.000485	CcSEcCtD
Tamoxifen—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000119	0.000479	CcSEcCtD
Tamoxifen—Anorexia—Methotrexate—lymphatic system cancer	0.000117	0.000472	CcSEcCtD
Tamoxifen—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000112	0.000451	CcSEcCtD
Tamoxifen—Insomnia—Methotrexate—lymphatic system cancer	0.000111	0.000448	CcSEcCtD
Tamoxifen—Paraesthesia—Methotrexate—lymphatic system cancer	0.00011	0.000444	CcSEcCtD
Tamoxifen—Dyspnoea—Methotrexate—lymphatic system cancer	0.00011	0.000441	CcSEcCtD
Tamoxifen—Dyspepsia—Methotrexate—lymphatic system cancer	0.000108	0.000436	CcSEcCtD
Tamoxifen—Decreased appetite—Methotrexate—lymphatic system cancer	0.000107	0.00043	CcSEcCtD
Tamoxifen—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000106	0.000427	CcSEcCtD
Tamoxifen—Fatigue—Methotrexate—lymphatic system cancer	0.000106	0.000427	CcSEcCtD
Tamoxifen—Pain—Methotrexate—lymphatic system cancer	0.000105	0.000423	CcSEcCtD
Tamoxifen—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.0001	0.000405	CcSEcCtD
Tamoxifen—Urticaria—Methotrexate—lymphatic system cancer	9.76e-05	0.000393	CcSEcCtD
Tamoxifen—Abdominal pain—Methotrexate—lymphatic system cancer	9.71e-05	0.000391	CcSEcCtD
Tamoxifen—Hypersensitivity—Methotrexate—lymphatic system cancer	9.05e-05	0.000365	CcSEcCtD
Tamoxifen—Asthenia—Methotrexate—lymphatic system cancer	8.81e-05	0.000355	CcSEcCtD
Tamoxifen—Pruritus—Methotrexate—lymphatic system cancer	8.69e-05	0.00035	CcSEcCtD
Tamoxifen—Diarrhoea—Methotrexate—lymphatic system cancer	8.41e-05	0.000339	CcSEcCtD
Tamoxifen—Dizziness—Methotrexate—lymphatic system cancer	8.12e-05	0.000327	CcSEcCtD
Tamoxifen—Vomiting—Methotrexate—lymphatic system cancer	7.81e-05	0.000315	CcSEcCtD
Tamoxifen—Rash—Methotrexate—lymphatic system cancer	7.75e-05	0.000312	CcSEcCtD
Tamoxifen—Dermatitis—Methotrexate—lymphatic system cancer	7.74e-05	0.000312	CcSEcCtD
Tamoxifen—Headache—Methotrexate—lymphatic system cancer	7.7e-05	0.00031	CcSEcCtD
Tamoxifen—Nausea—Methotrexate—lymphatic system cancer	7.3e-05	0.000294	CcSEcCtD
